Ben F. Brian, IV - Publications
Affiliations: | Pharmacology | University of Minnesota - Minneapolis |
Year | Citation | Score | |||
---|---|---|---|---|---|
2022 | Brian BF, Sauer ML, Greene JT, Senevirathne SE, Lindstedt AJ, Funk OL, Ruis BL, Ramirez LA, Auger JL, Swanson WL, Nunez MG, Moriarity BS, Lowell CA, Binstadt BA, Freedman TS. A dominant function of LynB kinase in preventing autoimmunity. Science Advances. 8: eabj5227. PMID 35452291 DOI: 10.1126/sciadv.abj5227 | 0.642 | |||
2022 | Brian BF, Sjaastad FV, Freedman TS. SH3-domain mutations selectively disrupt Csk homodimerization or PTPN22 binding. Scientific Reports. 12: 5875. PMID 35393453 DOI: 10.1038/s41598-022-09589-9 | 0.651 | |||
2021 | Greene JT, Brian BF, Senevirathne SE, Freedman TS. Regulation of myeloid-cell activation. Current Opinion in Immunology. 73: 34-42. PMID 34601225 DOI: 10.1016/j.coi.2021.09.004 | 0.651 | |||
2020 | Brian BF, Guerrero CR, Freedman TS. Immunopharmacology and Quantitative Analysis of Tyrosine Kinase Signaling. Current Protocols in Immunology. 130: e104. PMID 32931655 DOI: 10.1002/Cpim.104 | 0.665 | |||
2019 | Brian BF, Jolicoeur AS, Guerrero CR, Nunez MG, Sychev ZE, Hegre SA, Sætrom P, Habib N, Drake JM, Schwertfeger KL, Freedman TS. Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells. Elife. 8. PMID 31282857 DOI: 10.7554/Elife.46043 | 0.677 | |||
Show low-probability matches. |